Please provide your email address to receive an email when new articles are posted on . Kim’s hypothesis arises partially from studies that showed that C3, when introduced to synthetic neutrophils, ...

AJMC ®: How has treatment of complement-driven diseases changed since 2007, when the first complement inhibitor, eculizumab, was approved? SMITH: The development of eculizumab followed our ...

CAMBRIDGE, Mass., Dec. 10, 2024 /PRNewswire/ -- Kira Pharmaceuticals, a global biotechnology company pioneering transformational complement therapies to treat immune-mediated diseases, today announced ...

Omeros also has identified MASP-3 as the protein that is critical to the activation of the complement system’s alternative pathway in humans, which is linked to a wide range of immune-related ...